Sasanuma H, Tsuda M, Morimoto S, et al. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes. Proc Natl Acad Sci U S A. 2018;115(45):E10642-E10651. doi:10.1073/pnas.1803177115PubMedDOIGoogle Scholar
Shee K, Jiang A, Varn FS, et al. Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER breast cancer. FASEB J. 2019;33(2):1644-1657. doi:10.1096/fj.201801241RPubMedDOIGoogle Scholar
De Marchi T, Kuhn E, Dekker LJ, et al. Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. J Proteome Res. 2016;15(4):1230-42. doi:10.1021/acs.jproteome.5b01119PubMedDOIGoogle Scholar
Rheinbay E, Parasuraman P, Grimsby J, et al. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017;547(7661):55-60. doi:10.1038/nature22992PubMedDOIGoogle Scholar
Giltnane JM, Hutchinson KE, Stricker TP, et al. Genomic profiling of ER breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9(402). doi:10.1126/scitranslmed.aai7993PubMedDOIGoogle Scholar
Shee K, Yang W, Hinds JW, et al. Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. J Exp Med. 2018;215(3):895-910. doi:10.1084/jem.20171818PubMedDOIGoogle Scholar
Berger AC, Korkut A, Kanchi RS, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. 2018;33(4):690-705.e9. doi:10.1016/j.ccell.2018.03.014PubMedDOIGoogle Scholar
Hoshida Y, Brunet JP, Tamayo P, Golub TR, Mesirov JP. Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One. 2007;2(11):e1195. doi:10.1371/journal.pone.0001195PubMedDOIGoogle Scholar
Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol. 2006;102(1-5):71-8. doi:10.1016/j.jsbmb.2006.09.025PubMedDOIGoogle Scholar
Mootha VK, Handschin C, Arlow D, et al. Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci U S A. 2004;101(17):6570-5. doi:10.1073/pnas.0401401101PubMedDOIGoogle Scholar